MedTrace Logo

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

NCT06644404 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-10-16

No results posted yet for this study

Summary

This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults

Conditions

  • Healthy

Interventions

DRUG

DWP16001 0.3mg

1 tablet, Orally, Once daily single dose

DRUG

DWC202407 1,000mg

1 tablet, Orally, Twice daily

DRUG

DWC202408 2mg

1 tablet, Orally, Once daily single dose

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-26
Primary Completion
2024-12-03
Completion
2025-04-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644404 on ClinicalTrials.gov